NCT00543595已完成2 期
MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 154
研究概览
简要总结
This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have Type 2 Diabetes
- •18 to 65 years of age
排除标准
- •History of Type 1 Diabetes Mellitus
- •Have been treated with insulin in the past 8 weeks
- •On a weight loss program and have ongoing weight loss
- •Taking weight loss medication
- •Have had surgery requiring general anesthesia in the past 30 days or have a planned surgery
- •Have taken another investigational drug in the last 8 weeks
- •Have active liver disease
- •Have a history of major surgery involving gastric or intestinal bypass
研究者
相似试验
终止
2 期
Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)Type 2 Diabetes MellitusHypertensionNCT00806585Merck Sharp & Dohme LLC620
终止
2 期
MK0767 in Type 2 Diabetes (0767-012)Type 2 Diabetes MellitusNCT00543556Merck Sharp & Dohme LLC514
已完成
2 期
MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)Type 2 Diabetes MellitusNCT00371007Merck Sharp & Dohme LLC126
已完成
2 期
Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a SulfonylureaDiabetes MellitusNCT00036192Astellas Pharma Inc200
已完成
2 期
A Phase II Study of Single Agent MEK162 in Patients With Advanced MelanomaBRAF or NRAS Mutant Metastatic MelanomaNCT01320085Pfizer183